Which Is More Deadly: Ovarian or Uterine Cancer?

Ovarian cancer is substantially more deadly than uterine cancer. A population-based study of women diagnosed in 2010 found that roughly 69% of uterine cancer patients were cured, compared with just 32% for ovarian cancer, making the ovarian cure fraction less than half that of its uterine counterpart.¹ That gap, though, hides important nuances. Certain aggressive subtypes of uterine cancer rival ovarian cancer in lethality, and rising obesity rates are pushing uterine cancer incidence and mortality upward in ways that could narrow the overall disparity over time.

The Numbers Behind the Survival Gap

The simplest way to compare the two cancers is to look at what researchers call the “cure fraction,” which estimates the proportion of patients who will eventually have the same life expectancy as the general population. For women diagnosed with uterine (corpus uteri) cancer in 2010, that fraction was about 69% across all ages. Younger women fared even better: those diagnosed before age 55 had cure fractions above 80%, while the rate was 76% for women aged 55 to 64 and 67% for those 65 to 74.¹

Ovarian cancer tells a starkly different story. The overall cure fraction was 32% for women diagnosed in 2010, and it fell sharply with age: about 50% for women aged 45 to 54, 38% at 55 to 64, and just 27% at 65 to 74.¹ That downward slide with age is common in many cancers, but it is especially steep for ovarian cancer, where older patients are more likely to present with advanced disease and tolerate aggressive treatment less well.

Both cancers did see modest improvements between 2000 and 2010. The uterine cure fraction rose by about two percentage points and the ovarian by four. But that four-point gain for ovarian cancer still left it far behind, underscoring how entrenched the survival disadvantage is.

Why Ovarian Cancer Is So Hard to Catch Early

The single biggest reason ovarian cancer kills at higher rates is that it is usually diagnosed late. The ovaries sit deep in the pelvis, and tumors growing on them produce symptoms that are easy to dismiss: bloating, pelvic pressure, feeling full quickly, urinary urgency. These complaints overlap with dozens of benign conditions, and many women (and their doctors) attribute them to digestive issues or aging for months before cancer is considered.² By the time imaging or surgery reveals the cancer, it has often spread beyond the ovaries.

Uterine cancer, by contrast, sends a much clearer signal. Abnormal vaginal bleeding, particularly any bleeding after menopause, prompts medical evaluation. A systematic review and meta-analysis found that detection strategies focused on postmenopausal bleeding have the potential to capture as many as 90% of endometrial cancers, though the vast majority of women who experience such bleeding will not turn out to have cancer.³ That early warning system means most uterine cancers are found while still confined to the uterus, when surgery alone is often curative.

The Screening Problem

You might wonder whether routine screening could close the gap for ovarian cancer the way mammography and Pap smears have helped with breast and cervical cancers. Researchers have tried. The two largest trials, involving more than 270,000 women combined, tested blood-marker screening (CA-125) and transvaginal ultrasound against no screening. Neither approach reduced ovarian cancer deaths.⁴ The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), the largest randomized trial of its kind, confirmed that even though multimodal screening did detect more cancers at earlier stages, that shift did not translate into fewer deaths.⁵ As a result, no major guidelines recommend routine ovarian cancer screening for average-risk women.

Uterine cancer screening faces its own limitations. Transvaginal ultrasound can measure the thickness of the uterine lining, and thicker linings raise suspicion, but screening asymptomatic women this way has not been shown to be medically useful or cost-effective.⁶ Ultrasound performs better once a woman already has symptoms: a meta-analysis of diagnostic accuracy in asymptomatic postmenopausal women found that the test’s ability to spot cancer varies considerably depending on the thickness threshold chosen, with lower cutoffs catching more cases but flagging more false positives.⁷ The practical upshot is that for uterine cancer, the symptom itself (bleeding) functions as the screening tool, and it works reasonably well. Ovarian cancer has no equivalent.

How the Two Cancers Spread Differently

The anatomy of the ovaries and uterus helps explain why one cancer is so much harder to control. The ovaries are essentially exposed to the abdominal cavity. When ovarian cancer cells break free, they can float through peritoneal fluid and seed themselves across the lining of the abdomen. Patients are often diagnosed with widespread peritoneal metastasis and the buildup of fluid in the abdominal cavity known as ascites.⁸ This pattern of spread is difficult to treat surgically and tends to recur even after aggressive removal.

Uterine cancer, by comparison, typically grows inward through the muscle wall of the uterus (the myometrium) before reaching the lymphatic or vascular system. A large meta-analysis of nearly 69,000 patients found that deeper invasion into the muscle wall was linked to roughly a threefold higher rate of lymph node spread and a twofold higher rate of recurrence.⁹ The depth of muscle invasion, along with cervical involvement and the pattern of how tumor cells infiltrate, helps predict which uterine cancers will behave more aggressively.¹⁰ But the key difference is that many uterine cancers are caught before that deeper invasion happens, because the bleeding symptom brings women in early. The cancer still has a physical barrier to cross before it can spread widely.

Aggressive Subtypes That Blur the Line

Averages can obscure important realities. Not all uterine cancers are slow-growing and curable, and not all ovarian cancers are rapidly fatal. Each disease has subtypes that behave very differently from the norm.

On the ovarian side, the dominant killer is high-grade serous ovarian cancer, which accounts for 70 to 80% of ovarian cancer deaths. Overall survival for this subtype has barely changed in decades despite improvements in surgery and chemotherapy.¹¹ It tends to present at advanced stages and to develop resistance to treatment over time.

On the uterine side, uterine serous carcinoma and uterine carcinosarcoma are uncommon but exceptionally dangerous. Together they make up roughly 15% of all endometrial cancer cases yet account for more than half of all endometrial cancer deaths.¹² Uterine serous carcinoma alone represents fewer than one in ten endometrial cancers but is responsible for a disproportionate share of mortality.¹³ These tumors behave more like ovarian cancer biologically: they can spread across the peritoneum even when the primary tumor is still small, and they respond poorly to standard hormonal treatments used for more common uterine cancer types.

If you are diagnosed with one of these aggressive uterine subtypes, the prognosis looks far closer to ovarian cancer than the reassuring 69% cure fraction suggests. The overall survival statistics for uterine cancer are buoyed by the large majority of cases that are low-grade and caught early.

Treatment Differences and the Challenge of Recurrence

For ovarian cancer, the standard approach combines aggressive surgical removal of all visible tumor (cytoreductive surgery) with platinum-based chemotherapy. Survival depends heavily on how thoroughly the surgeon can clear the disease. Women who had complete clearance of all visible tumor had a median overall survival of about 86 months, compared with 46 months for those with small amounts of residual disease and 37 months when more was left behind.¹⁴ Achieving that complete clearance often requires extensive, complex surgery.¹⁵

Even with successful surgery, recurrence is the central problem. Most ovarian cancer patients initially respond to platinum chemotherapy, but through repeated recurrences, the disease tends to become resistant. Once platinum resistance develops, treatment options narrow significantly and outcomes worsen.¹⁶ This cycle of response, recurrence, and eventual resistance is what makes ovarian cancer so difficult to cure in the long term.

Uterine cancer treatment is generally simpler in early stages. A hysterectomy removing the uterus and often the ovaries and fallopian tubes cures most women with disease confined to the uterus. Radiation and chemotherapy are added for higher-risk or more advanced cases. The recurrence rate for early-stage, low-grade uterine cancer is relatively low, and when the disease does come back, it is sometimes still manageable. The treatment burden and surgical complexity are typically less extreme than what advanced ovarian cancer demands.

Newer Therapies Are Shifting the Landscape

The most significant recent advances in gynecologic oncology have come from two drug classes: PARP inhibitors for ovarian cancer and immune checkpoint inhibitors for endometrial cancer. PARP inhibitors work by exploiting defects in tumor DNA repair. Several have been approved as maintenance therapy for advanced ovarian cancer, helping to delay recurrence after initial chemotherapy response.¹⁷ They are particularly effective in women whose tumors have deficiencies in a DNA repair pathway known as homologous recombination, which includes (but is not limited to) women with BRCA mutations.

For endometrial cancer, immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have shown strong results in tumors with a specific molecular feature called mismatch repair deficiency. These tumors accumulate many mutations, making them more visible to the immune system when the checkpoint brake is released. Molecular testing for this feature and for homologous recombination deficiency in ovarian tumors is now part of routine clinical care.¹⁸ Research is ongoing to extend these therapies to broader patient populations beyond the subgroups that benefit most clearly.

BRCA Mutations and Inherited Risk

Inherited mutations in the BRCA1 and BRCA2 genes are best known for their link to breast cancer, but they also dramatically raise ovarian cancer risk. A large combined analysis of 22 studies estimated the average cumulative risk of ovarian cancer by age 70 at about 39% for BRCA1 carriers and 11% for BRCA2 carriers.¹⁹ A prospective cohort study with longer follow-up through age 80 put the figures somewhat higher: 44% for BRCA1 and 17% for BRCA2.²⁰ Either way, a BRCA1 carrier faces a lifetime ovarian cancer risk that is roughly 20 to 40 times higher than the general population rate.

These mutations also influence treatment. As mentioned, BRCA-related tumors tend to respond well to PARP inhibitors because their DNA repair machinery is already compromised. Women who know their BRCA status before a diagnosis can also take preventive steps: prophylactic removal of the ovaries and fallopian tubes after completing childbearing substantially reduces ovarian cancer risk. There is no comparable single-gene risk factor that has as large an impact on uterine cancer, though Lynch syndrome (an inherited condition involving mismatch repair genes) does raise endometrial cancer risk and is worth testing for in families with a pattern of colon, uterine, or ovarian cancers.

The Obesity Connection and Rising Uterine Cancer Rates

While ovarian cancer incidence has actually been declining modestly in recent decades, uterine cancer has been heading in the opposite direction, and obesity is a major reason. Population-level data show a parallel rise in obesity and endometrial cancer incidence over four decades, including a significant and concerning increase in women younger than 45. The average age at diagnosis of endometrial cancer dropped from about 64 to 61 years over the study period.²¹

The link between obesity and endometrial cancer involves excess estrogen. Fat tissue converts certain hormones into estrogen, and the uterine lining is highly sensitive to estrogen stimulation. More body fat means more estrogen exposure over time, which promotes the growth of endometrial cells. There is a lag between the rise in obesity and the rise in cancer: researchers estimate a latency period of roughly 10 to 15 years from obesity onset to the development of life-threatening obesity-related cancers. An inflection point in U.S. endometrial cancer mortality around 2013 likely reflects the cumulative effect of population-wide obesity trends from earlier decades.²²

This trend matters for the overall deadliness comparison. If uterine cancer becomes more common and increasingly strikes younger women or produces more aggressive tumors in the context of metabolic disease, its aggregate death toll could rise even as the per-case survival rate stays relatively good. The gap between ovarian and uterine cancer mortality, while still large, may narrow from the uterine side getting worse rather than the ovarian side improving.

Racial Disparities in Uterine Cancer Outcomes

One of the most troubling aspects of uterine cancer is how differently it behaves across racial groups. Black women with uterine cancer have, on average, worse survival outcomes than white women. Part of this disparity is biological: Black women are diagnosed with aggressive, non-endometrioid subtypes at substantially higher rates.²³ The uterine serous carcinoma and carcinosarcoma subtypes discussed earlier, which are responsible for a disproportionate share of endometrial cancer deaths, are overrepresented in Black women.

But tumor biology does not explain the entire gap. Access to timely care, quality of surgical treatment, follow-up resources, and insurance coverage all play roles. When researchers try to untangle these factors, systemic inequalities in health care keep emerging as contributors alongside the higher prevalence of aggressive tumor types. For a Black woman diagnosed with uterine cancer, the disease is more likely to behave aggressively and less likely to receive the same quality of care, a compounding disadvantage that makes “uterine cancer is usually curable” a less reassuring statement than it is for the average patient.

Ovarian cancer also shows racial disparities, but the survival differences between racial groups are less dramatic than in uterine cancer, partly because ovarian cancer outcomes are poor across all groups. The racial disparity conversation in gynecologic oncology right now is focused more heavily on the uterine cancer side, precisely because the rising mortality there is hitting some populations harder than others.

When the “Less Deadly” Cancer Becomes Dangerous

If you or someone you know receives a uterine cancer diagnosis, the instinct to look up survival statistics and feel reassured is understandable. And for the majority of cases, that reassurance is warranted. But several specific situations flip the script:

• Aggressive subtype: Uterine serous carcinoma, carcinosarcoma, and clear cell carcinoma behave far more dangerously than the common endometrioid type. Pathology results matter more than the organ of origin when it comes to predicting outcomes.
• Deep muscle invasion: When the tumor has grown deeply into the uterine wall, the risk of lymph node spread and recurrence rises sharply, and survival drops accordingly.
• Advanced stage at diagnosis: Uterine cancer found after it has left the uterus carries a prognosis much more in line with ovarian cancer than with early-stage endometrial cancer.
• Delayed care or inadequate surgery: The quality and completeness of surgical staging and treatment affects outcomes significantly, and disparities in access to expert gynecologic oncology care can turn a treatable cancer into a fatal one.

Conversely, early-stage ovarian cancer caught before it has spread beyond the ovary has a reasonably good prognosis. The problem is that this happens in a minority of cases. When people ask which cancer is “more deadly,” they are usually asking about the typical scenario, and the typical scenario for ovarian cancer involves later-stage disease, more complex treatment, eventual drug resistance, and lower odds of long-term cure. But individual prognosis depends far more on the specifics of the diagnosis than on which organ the cancer started in.